Calidi Biotherapeutics (CLDI) vs GRI Bio (GRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Calidi Biotherapeutics is the larger company by market cap ($3.8 million vs $3.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDI | GRI |
|---|---|---|
| Share price | $1.04 | $1.68 |
| Market cap | $3.82M | $3.67M |
| 1-day change | +2.97% | -9.19% |
| EPS (TTM) | $-36.47 | $-14.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.84 | $64.12 |
| 52-week low | $0.986 | $1.36 |
| Distance from 52-week high | -96.26% | -97.38% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1001.19% |
| Average volume | 255.53K | 328.06K |
| Shares outstanding | 3.68M | 2.19M |
| Employees | 29 | 3 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Healthcare · Biotechnology · 29 employees
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Healthcare · Biotechnology · 3 employees
CLDI vs GRI FAQ
Which is bigger, Calidi Biotherapeutics or GRI Bio?
Calidi Biotherapeutics (CLDI) is larger, with a market capitalization of $3.82M compared with $3.67M for GRI Bio (GRI).
Are Calidi Biotherapeutics and GRI Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.